Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission
Tóm tắt
To assess whether radiologic progression occurs during clinical remission in patients with rheumatoid arthritis (RA).
One hundred eighty‐seven patients with RA in clinical remission were followed up clinically and radiologically for 2 years. Clinical remission was defined according to a modification of the American College of Rheumatology criteria (i.e., the criterion of fatigue was omitted, and patients had to fulfill 4 of the 5 remaining criteria). Radiologic joint damage was assessed by the Sharp/van der Heijde method.
After 2 years of followup, remission persisted in 52% of patients. The median radiologic score for the total group of patients increased from 21 (interquartile range [IQR] 5, 65) at the time of entry to 25 (IQR 7, 72) after 2 years (
Although rare, clinically relevant progression of joint damage does occur in patients with RA in prolonged remission. This suggests the need for markers that predict progression during periods of low disease activity and for drugs that prevent damage that is independent of disease activity.
Từ khóa
Tài liệu tham khảo
Van Zeben D, 1994, The severity of rheumatoid arthritis: a 6‐year followup study of younger women with symptoms of recent onset, J Rheumatol, 21, 1620
Wolfe F, 1996, The natural history of rheumatoid arthritis, J Rheumatol, 44, 13
Wolfe F, 1985, Remission in rheumatoid arthritis, J Rheumatol, 12, 245
Ritchie DM, 1968, Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis, Q J Med, 37, 393
Shrout PE, 1979, Intraclass correlations: uses in assessing rater reliability, Psychol Bull, 86, 720, 10.1037/0033-2909.86.2.420
Lassere MN, 2001, Robustness and generalizability of smallest detectable difference in radiological progression, J Rheumatol, 28, 911
Van Zeben D, 1993, Factors predicting outcome of rheumatoid arthritis: results of a follow‐up study, J Rheumatol, 20, 1288
Garnero P, 2002, Short‐term reduction in urinary CTX‐II, a marker of cartilage degradation, predicts long‐term radiological progression in patients with rheumatoid arthritis (RA) treated with disease‐modifying antirheumatic therapy (DMARD), Arthritis Rheum, 46, S376